Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Meglumine adenosine cyclophosphate composite medicament

A kind of meglumine cyclophosphate and the technology of meglumine cyclophosphate, which are applied in the field of meglumine cyclophosphate combination medicine and its preparation, and achieve the effect of solid forming plump

Active Publication Date: 2012-01-04
安徽延寿堂药业有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Adverse reactions of cyclic adenosine monophosphate meglumine and cyclic adenosine monophosphate in the prior art include: allergy, fever, rash, headache, back pain, abdominal pain, myalgia, nausea, weakness of limbs, numbness of hands and feet during intravenous infusion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The meglumine cyclic adenosine monophosphate combination medicine provided by the invention is made of the following medicinal ingredients in parts by weight:

[0025] Meglumine Cyclic Adenosine 20

[0026] Lysine Aspirin 100

[0027] Mixture of reduced glutathione and vitamin C at a weight ratio of 1:10-15 200

[0028] The cyclic adenosine monophosphate meglumine may be replaced by cyclic adenosine monophosphate, and the parts by weight are calculated by the cyclic adenosine monophosphate meglumine.

[0029] The present invention also provides a method for preparing the above-mentioned combination medicine, the steps are as follows:

[0030] (1). Take water for injection whose weight is 50-150 times of the weight of the described meglumine cyclophosphate, and mix the described meglumine cyclophosphate and reduced glutathione respectively under stirring at 80-100 rpm Glycine, vitamin C, and lysine aspirin are completely dissolved to obtain a combined drug solution; ...

Embodiment 2

[0038] The meglumine cyclic adenosine monophosphate combination medicine provided by the invention is made of the following medicinal ingredients in parts by weight:

[0039] Meglumine Cyclophosphate 60

[0040] Lysine Aspirin 200

[0041] Mixture of reduced glutathione and vitamin C at a weight ratio of 1:10-15 300

[0042] Cyclic adenosine monophosphate meglumine may be replaced by cyclic adenosine monophosphate, and the parts by weight are calculated by cycloadenosine monophosphate meglumine.

[0043] The present invention also provides a method for preparing the above-mentioned combination medicine, the steps are as follows:

[0044] (1). Take water for injection whose weight is 50-150 times of the weight of the described meglumine cyclophosphate, and mix the described meglumine cyclophosphate and reduced glutathione respectively under stirring at 80-100 rpm Glycine, vitamin C, and lysine aspirin are completely dissolved to obtain a combined drug solution;

[0045] (2)...

Embodiment 3

[0052] The meglumine cyclic adenosine monophosphate combination medicine provided by the invention is made of the following medicinal ingredients in parts by weight:

[0053] Meglumine Cyclophosphate 40

[0054] Lysine Aspirin 135

[0055] Mixture of reduced glutathione and vitamin C at a weight ratio of 1:10-15 276

[0056]The cyclic adenosine monophosphate meglumine may be replaced by cyclic adenosine monophosphate, and the parts by weight are calculated by the cyclic adenosine monophosphate meglumine.

[0057] The present invention also provides a method for preparing the above-mentioned combination medicine, the steps are as follows:

[0058] (1). Take water for injection whose weight is 50-150 times of the weight of the described meglumine cyclophosphate, and mix the described meglumine cyclophosphate and reduced glutathione respectively under stirring at 80-100 rpm Glycine, vitamin C, and lysine aspirin are completely dissolved to obtain a combined drug solution;

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a meglumine adenosine cyclophosphate composite medicament or an adenosine cyclophosphate composite medicament which is prepared from pharmacodynamic components by weight part: 20 to 60 parts of meglumine adenosine cyclophosphate or adenosine cyclophosphate, 100 to 200 parts of lysine aspirin and 200 to 300 parts of mixture of reduced glutathione and vitamin C with the weight ratio of 1: (10 to 15). The invention also relates to a preparation method. The meglumine adenosine cyclophosphate composite medicament or the adenosine cyclophosphate composite medicament eliminates fever, tetter, pain and other adverse effects of meglumine adenosine cyclophosphate or adenosine cyclophosphate prepared by the prior art.

Description

technical field [0001] The invention relates to a combination drug of adenosine monophosphate meglumine and a preparation method thereof. Background technique [0002] Cyclic adenosine monophosphate (cAMP) is an important substance involved in the regulation of biological functions such as substance metabolism in cells. It has the effects of nourishing the myocardium, positive muscle strength, relaxing blood vessels, and resisting cardiac arrhythmia. As the second messenger of life information transmission, cAMP can make ATP-Ca on the cell membrane 2+ Ca in the complex 2+ released to alter the function of the cell membrane; also Ca in the sarcoplasmic reticulum 2+ Enter muscle fibers, thereby enhancing myocardial contractility and enhancing cardiac output. and dilate the coronary arteries. Cyclic adenosine monophosphate meglumine is an organic salt of cyclic adenosine monophosphate. Adverse reactions of cyclic adenosine monophosphate meglumine and cyclic adenosine mono...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7076A61K31/616A61K47/22A61K47/20A61K47/18A61K47/14A61K9/19A61P9/10
Inventor 邓学峰蔡海德
Owner 安徽延寿堂药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com